# Lixisenatide for type 2 diabetes.

> PubMed lists PMID 28118649 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2017-01-30 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28118649-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28118649-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-28118649-lixisenatide-v1.json
- Content SHA-256: `ca0c72bee11bab4a920024267d9803a72332fe9f19ff6235d8f6d7e5f4ff074a`

## Claims and source pins

### Headline

Lixisenatide for type 2 diabetes. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

### Summary

PubMed lists PMID 28118649 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2017-01-30 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

### Paragraph 1

PubMed lists PMID 28118649 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2017-01-30 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`](#source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c))

## Sources

<a id="source-pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c"></a>
- **Lixisenatide for type 2 diabetes. · retained source version 1:2026-01-27:current:8c455dbe496c1c83123ead569de74aab5ccefde238443fd8fab14cb2fad228c8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28118649/) (`pubmed-observation-pmid-28118649-2026-01-27-8c455dbe496c`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Lixisenatide for type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-28118649-lixisenatide-v1.json SHA-256: ca0c72bee11bab4a920024267d9803a72332fe9f19ff6235d8f6d7e5f4ff074a.